Logo image of AZTR

AZITRA INC (AZTR) Stock Fundamental Analysis

NYSEARCA:AZTR - NYSE Arca - US05479L2034 - Common Stock - Currency: USD

0.295  +0.01 (+3.18%)

After market: 0.285 -0.01 (-3.39%)

Fundamental Rating

2

Overall AZTR gets a fundamental rating of 2 out of 10. We evaluated AZTR against 561 industry peers in the Biotechnology industry. Both the profitability and financial health of AZTR have multiple concerns. AZTR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AZTR has reported negative net income.
In the past year AZTR has reported a negative cash flow from operations.
AZTR had negative earnings in each of the past 5 years.
AZTR had a negative operating cash flow in each of the past 5 years.
AZTR Yearly Net Income VS EBIT VS OCF VS FCFAZTR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of AZTR (-121.86%) is worse than 80.04% of its industry peers.
Looking at the Return On Equity, with a value of -157.37%, AZTR is doing worse than 65.06% of the companies in the same industry.
Industry RankSector Rank
ROA -121.86%
ROE -157.37%
ROIC N/A
ROA(3y)-185.51%
ROA(5y)-136.52%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AZTR Yearly ROA, ROE, ROICAZTR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

AZTR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AZTR Yearly Profit, Operating, Gross MarginsAZTR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -50K -100K

More info and screens

3

2. Health

2.1 Basic Checks

AZTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AZTR has been increased compared to 1 year ago.
AZTR has a better debt/assets ratio than last year.
AZTR Yearly Shares OutstandingAZTR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
AZTR Yearly Total Debt VS Total AssetsAZTR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

AZTR has an Altman-Z score of -13.70. This is a bad value and indicates that AZTR is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -13.70, AZTR is not doing good in the industry: 79.86% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.00 indicates that AZTR is not too dependend on debt financing.
The Debt to Equity ratio of AZTR (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.7
ROIC/WACCN/A
WACC9.89%
AZTR Yearly LT Debt VS Equity VS FCFAZTR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M 10M -10M 15M

2.3 Liquidity

AZTR has a Current Ratio of 3.80. This indicates that AZTR is financially healthy and has no problem in meeting its short term obligations.
AZTR's Current ratio of 3.80 is in line compared to the rest of the industry. AZTR outperforms 45.10% of its industry peers.
AZTR has a Quick Ratio of 3.80. This indicates that AZTR is financially healthy and has no problem in meeting its short term obligations.
AZTR's Quick ratio of 3.80 is in line compared to the rest of the industry. AZTR outperforms 46.70% of its industry peers.
Industry RankSector Rank
Current Ratio 3.8
Quick Ratio 3.8
AZTR Yearly Current Assets VS Current LiabilitesAZTR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

4

3. Growth

3.1 Past

AZTR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -155.93%.
The Revenue for AZTR has decreased by -98.90% in the past year. This is quite bad
AZTR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -59.15% yearly.
EPS 1Y (TTM)-155.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94%
Revenue 1Y (TTM)-98.9%
Revenue growth 3Y-59.15%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

AZTR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.55% yearly.
The Revenue is expected to grow by 195.91% on average over the next years. This is a very strong growth
EPS Next Y64.39%
EPS Next 2Y30.29%
EPS Next 3Y17.55%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y195.91%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AZTR Yearly Revenue VS EstimatesAZTR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
AZTR Yearly EPS VS EstimatesAZTR Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AZTR. In the last year negative earnings were reported.
Also next year AZTR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AZTR Price Earnings VS Forward Price EarningsAZTR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AZTR Per share dataAZTR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as AZTR's earnings are expected to grow with 17.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.29%
EPS Next 3Y17.55%

More info and screens

0

5. Dividend

5.1 Amount

AZTR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AZITRA INC

NYSEARCA:AZTR (5/20/2025, 8:04:02 PM)

After market: 0.285 -0.01 (-3.39%)

0.295

+0.01 (+3.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24 2025-02-24/bmo
Earnings (Next)N/A N/A
Inst Owners3.59%
Inst Owner Change105.12%
Ins Owners0.18%
Ins Owner Change0%
Market Cap4.42M
Analysts82.86
Price Target2.55 (764.41%)
Short Float %22.07%
Short Ratio2.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-22.45%
Min EPS beat(2)-99.24%
Max EPS beat(2)54.34%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-28.57%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 589.21
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 0.81
EV/EBITDA N/A
EPS(TTM)-7.59
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0
BVpS0.38
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -121.86%
ROE -157.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-185.51%
ROA(5y)-136.52%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.55%
Cap/Sales 114.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.8
Quick Ratio 3.8
Altman-Z -13.7
F-Score3
WACC9.89%
ROIC/WACCN/A
Cap/Depr(3y)34.64%
Cap/Depr(5y)206.62%
Cap/Sales(3y)51.41%
Cap/Sales(5y)122.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-155.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94%
EPS Next Y64.39%
EPS Next 2Y30.29%
EPS Next 3Y17.55%
EPS Next 5YN/A
Revenue 1Y (TTM)-98.9%
Revenue growth 3Y-59.15%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y195.91%
EBIT growth 1Y-44.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.32%
OCF growth 3YN/A
OCF growth 5YN/A